Scaling the Next Generation of T Cell Therapies

This webinar, brought to you by Cytiva, will be hosted live and available on-demand. 

Thursday, June 18th, 2026
10:00 – 11:00 CEST 

First-generation autologous chimeric antigen receptor (CAR)-T cell therapies have demonstrated significant clinical success in hematologic malignancies, but challenges related to target scope, manufacturing complexity, scalability, and cost continue to limit broader application. Emerging approaches in T cell engineering are expanding therapeutic opportunities through new targeting strategies and alternative manufacturing models designed to support wider clinical accessibility.

In this webinar, brought to you by Cytiva, Luke Pase, chief technology officer at Anocca, and Prof. Fujiwara, professor and clinical investigator at Mie University, will discuss advances shaping the next generation of T cell therapies. The session will examine how T cell receptor-engineered T cell (TCR-T) therapies enable targeting of intracellular antigens beyond conventional cell surface recognition, alongside the development of allogeneic CAR-γδ T cell therapies as off-the-shelf alternatives to autologous approaches. Speakers will also discuss how non-viral gene editing, scalable manufacturing strategies, and digital process management systems are supporting clinical translation and broader patient access.

Topics to be covered

• Expanding therapeutic targeting through TCR-T approaches
• Development of allogeneic CAR-γδ T cell therapies for solid tumors
• Non-viral gene editing strategies for scalable cell therapy production
• Digital manufacturing and process control in cell therapy workflows
• Challenges in scaling next-generation T cell therapies for clinical translation

	Luke Pase Chief Technology Officer Anocca
	Prof. Fujiwara Professor Mie University